Sodium-glucose cotransporter 2 inhibitors alternatives
Pro Research Analysisby 
Searched over 400M research papers
Alternatives to Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Key Options and Comparisons
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as SGLT2 Inhibitor Alternatives
GLP-1 receptor agonists are a major alternative to SGLT2 inhibitors for patients with type 2 diabetes. Both drug classes lower all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and kidney failure, but there are important differences. SGLT2 inhibitors are more effective at reducing mortality and hospital admissions for heart failure, while GLP-1 receptor agonists are better at reducing non-fatal stroke. Each class has distinct side effects: SGLT2 inhibitors are more likely to cause genital infections, while GLP-1 receptor agonists may cause severe gastrointestinal events. Both may help with weight loss, but the evidence is less certain. The choice between these options should be based on individual patient risk profiles and comorbidities .
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors as an Alternative
DPP-4 inhibitors are another alternative for glucose lowering in type 2 diabetes. Compared to SGLT2 inhibitors, DPP-4 inhibitors are associated with a higher risk of anemia and related hospitalizations. SGLT2 inhibitors show a lower prevalence of anemia and a reduced need for anemia treatment compared to DPP-4 inhibitors, making them preferable for patients at risk of anemia .
Metformin and Other Traditional Glucose-Lowering Agents
Metformin remains the first-line therapy for type 2 diabetes and is often used before considering SGLT2 inhibitors or their alternatives. Other traditional agents, such as sulfonylureas and insulin, are also available but may carry a higher risk of hypoglycemia and do not offer the same cardiovascular or renal benefits as SGLT2 inhibitors or GLP-1 receptor agonists Palmer2021Scheen2020.
Cardiovascular and Renal Benefits: SGLT2 Inhibitors vs. Alternatives
SGLT2 inhibitors and GLP-1 receptor agonists both provide cardiovascular and renal protection, but SGLT2 inhibitors are especially effective in reducing heart failure hospitalizations and slowing the progression of kidney disease. These benefits are seen even in patients with chronic kidney disease or heart failure, regardless of diabetes status. In contrast, the cardiovascular and renal benefits of DPP-4 inhibitors and other traditional agents are less pronounced Palmer2021Fonseca-Correa2021Heerspink2016+1 more.
Safety and Side Effect Profiles
When considering alternatives, it is important to weigh the side effect profiles. SGLT2 inhibitors are linked to genital infections but have a low risk of severe hypoglycemia. GLP-1 receptor agonists may cause gastrointestinal side effects. DPP-4 inhibitors are generally well-tolerated but may not provide the same level of cardiovascular or renal protection Palmer2021Steinmetz2025Scheen2020.
Conclusion
GLP-1 receptor agonists and DPP-4 inhibitors are the main alternatives to SGLT2 inhibitors for type 2 diabetes management. GLP-1 receptor agonists offer similar overall benefits, with some differences in cardiovascular outcomes and side effects. DPP-4 inhibitors are less effective for cardiovascular and renal protection and may increase anemia risk compared to SGLT2 inhibitors. The choice of therapy should be individualized based on patient risk factors, comorbidities, and treatment goals.
Sources and full results
Most relevant research papers on this topic